Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2005 | 1 |
2015 | 2 |
2016 | 1 |
2017 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966. doi: 10.1158/1078-0432.CCR-19-1133. Epub 2019 Sep 10.
Clin Cancer Res. 2019.
PMID: 31506387
Free PMC article.
Clinical Trial.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F.
Palanca-Wessels MC, et al. Among authors: yalamanchili s.
Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.
Lancet Oncol. 2015.
PMID: 25925619
Clinical Trial.
Item in Clipboard
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, Agarwal P, Dere RC, Hsieh HJ, Jones S, Chu YW, Cheson BD.
Advani RH, et al. Among authors: yalamanchili s.
Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. doi: 10.1158/1078-0432.CCR-16-0772. Epub 2016 Sep 6.
Clin Cancer Res. 2017.
PMID: 27601593
Free PMC article.
Clinical Trial.
Item in Clipboard
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H.
Kipps TJ, et al. Among authors: yalamanchili s.
Leuk Lymphoma. 2015;56(10):2826-33. doi: 10.3109/10428194.2015.1030638. Epub 2015 May 12.
Leuk Lymphoma. 2015.
PMID: 25797560
Free PMC article.
Clinical Trial.
Item in Clipboard
Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy.
Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S.
Sulkowski M, et al. Among authors: yalamanchili s.
Clin Pharmacol Ther. 2005 Mar;77(3):214-24. doi: 10.1016/j.clpt.2004.09.008.
Clin Pharmacol Ther. 2005.
PMID: 15735615
Clinical Trial.
Item in Clipboard
Cite
Cite